MK615, A Compound Extract from the Japanese Apricot “Prunus mume” Inhibits In vitro Cell Growth and Interleukin-8 Expression in Non-small Cell Lung Cancer Cells

Noriaki Sunaga1*, Katsuya Hiraishi2, Tamotsu Ishizuka3, Kyoichi Kaira4, Yasuki Iwasaki5, Fumie Jimma6, Masakazu Adachi7 and Masatomo Mori8

1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan
2Adabio Co., Ltd., 21-2 Kenzaki-machi, Takasaki, Gunma 370-0883, Japan

Abstract

The Japanese apricot “Prunus mume,” which is also known as the Ume fruit in Japan, is a centuries-old traditional Japanese medicine, and it is a commonly consumed food. MK615, a compound extract from Ume fruits, has been shown to have anti-tumor and anti-inflammatory effects. In this study, we assessed the effects of MK615 on the in vitro growth of nine non-small cell lung cancer (NSCLC) cell lines and the HBEC4 immortalized bronchial epithelial cell line. While MK615 inhibited the in vitro cell growth of the majority of the NSCLC cell lines, the growth-inhibitory effects varied among the cell lines, and some cell lines exhibited MK615 resistance. In the H1299 and H157 NSCLC cell lines that are highly sensitive to MK615, the induction of autophagy was observed after MK615 treatment. In addition, cell-cycle analysis showed that MK615 increased the proportion of cells in the G0-G1 phase in H1299 and H157 cells. In H1792 cells that overexpress IL-8, MK615 down-regulated IL-8 expression at the mRNA and protein levels in a dose-dependent manner. These results suggest that MK615 has multiple anti-tumor activities including the inhibition of cell proliferation, autophagy induction, G0-G1 cell cycle arrest and the down-regulation of IL-8 expression in NSCLC cells.

Introduction

Lung cancer is the leading cause of cancer related deaths throughout the world [1]. Lung cancer is divided into two major histological subtypes: small cell lung cancer and non-small cell lung cancer (NSCLC), and the latter represents 80-85% of all lung cancers [2]. The majority of patients with NSCLC have locally advanced or metastatic disease at initial diagnosis, and systemic chemotherapy for such patients remains marginally effective. Moreover, chemotherapeutic agents occasionally cause serious adverse effects. Thus, there is an urgent need to develop more effective and less toxic anti-tumor agents for NSCLC therapy.

The Japanese apricot “Prunus mume” (Figure 1A), which is also known as the Ume fruit in Japan, is a centuries-old traditional Japanese medicine, and it is a commonly consumed food. Ume fruits contain many natural chemical substances including citric acid, malic acid and triterpenoids [3]. MK615 (Figure 1B), a compound extract from Ume fruits, has been shown to have anti-tumor effects against various human cancers including malignant melanoma [4] and colon [5], breast [6], hepatocellular [7,8], esophageal [9] and pancreatic cancers [10]. However, the MK615 anti-tumor effects on lung cancer remain to be elucidated. Furthermore, a previous study demonstrated that MK615 inhibits the release of inflammatory cytokines, interleukin-6 and tumor necrosis factor-alpha by mitogen-activated protein kinase (MAPK) and NF-kB p65 activation in lipopolysaccharide (LPS)-induced macrophage-like cells [11]. This finding suggests that MK615 potentially inhibits tumor-related cytokine production. Here we describe the inhibitory effects of MK615 on in vitro cell growth and interleukin-8 (IL-8) expression in NSCLC cells.

Materials and Methods

MK615 preparation

MK615 (Figure 1B) represents the extracted components from Ume fruits [5-8]. The MK615 preparation procedure was previously described [6]. Briefly, Ume fruits were squeezed in a press, and the juice was heated and concentrated. The condensed extract was dissolved in water and neutralized by NaOH. The MK615 solution was then sterilized in an autoclave.

*Corresponding author: Noriaki Sunaga, MD, Department of Medicine and Molecular Science, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan; Tel: +81-27-220-8136; Fax: +81-27-220-8136; E-mail: nsunaga@showa.gunma-u.ac.jp

Received February 28, 2012; Accepted March 09, 2012; Published March 12, 2012

Citation: Sunaga N, Hiraishi K, Ishizuka T, Kaira K, Iwasaki Y, et al. (2011) MK615, A Compound Extract from the Japanese Apricot “Prunus mume” Inhibits In vitro Cell Growth and Interleukin-8 Expression in Non-small Cell Lung Cancer Cells. J Cancer Sci Ther 2011, S11:002. doi:10.4172/1948-5956.S11-002

Copyright: © 2011 Sunaga N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cell lines and culture conditions

Nine NSCLC cell lines (i.e., NCI-H157, NCI-H441, NCI-H460, NCI-H661, NCI-H838, NCI-H1299, NCI-H1395, NCI-H1792 and HCC827) [12,13] and the HBE4C immortalized human bronchial epithelial cell line [14] were kindly provided by Drs. John D. Minna and Adi F. Gazdar of the University of Texas Southwestern Medical Center at Dallas. The cancer cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum. The HBE4C4 cells were cultured in Keratinocyte-SFM medium (Invitrogen, Carlsbad, CA) containing 50 µg/ml bovine pituitary extract (Invitrogen) and 5 ng/ml EGF (Invitrogen).

Cell growth assay

Twenty-four hours after plating the cells (H1299: 1 × 10⁵ cells; H1395: 2 × 10⁵ cells; and all other cell lines: 1 × 10⁵ cells) on 6-well plates, the cells were treated with 1.5, and 10 µl/ml MK615. After 48 and 96 h, the trypan blue-negative viable cells were counted.

Immunofluorescence staining

Autophagy was evaluated by immunostaining of microtubule-associated protein 1 light chain 3 (LC3), which is an autophagosomal marker [15,16]. The cells were treated with or without 10 µl/ml MK615 and harvested after 6 h. The cells were then mounted on glass slides using a Cytospin (Shandon, Pittsburgh, PA; model Cytospin 2). The mounted cell specimens were fixed with 4% paraformaldehyde for 10 min at room temperature. The specimens were incubated with an anti-LC3 antibody (Medical & Biological Laboratories Co., Nagoya, Japan) at 4°C overnight. The specimens were subsequently incubated with a FITC-conjugated antibody (MP Biomedicals-Cappel, Irvine, CA) for 1 h at room temperature. The specimens were then immediately observed for the intracellular localization of FITC using a fluorescence microscope (Olympus, Tokyo, Japan; Model AX80). Non-treated cells (i.e., those incubated without MK615) were used as control specimens.

Western blotting

After treatment with or without 10 µl/ml MK615 for 4 and 8 h, the cells were washed with phosphate-buffered saline, and lysed with Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA) containing 2% β-mercaptoethanol. Cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using AnykD Criterion TGX precast gel (Bio-Rad Laboratories), and electro transferred by semi-dry blotting (Bio-Rad Laboratories) onto a PVDF membrane. After the membrane was blocked with 5% skim milk in TBS buffer containing 0.1% Tween-20, it was incubated with 0.56 mM 3, 3’-Diaminobenzidine and 2% H2O2 in 50 mM Tris-HCl, pH7.6.

Cell cycle analysis

Twenty-four hours after MK615 treatment, the cells were harvested and fixed with ethanol. The cells were then treated with 200 µg/ml RNase A, stained with 10 µg/ml propidium iodide, and analyzed on a FACS Caliber instrument using Cell Quest software (Nippon Becton Dickinson, Tokyo, Japan).

Quantitative real-time RT-PCR

IL-8 mRNA expression was evaluated using quantitative real-time RT-PCR [17]. Briefly, 24 h after 1 × 10⁵ cells were plated in each well of a 6-well plate, the culture medium was replaced with 2 ml of growth medium containing MK615 at different concentrations. After 24 h, the cells were harvested, and total RNA was extracted using an RN easy mini kit (Qiagen, Chatworth, CA), and cDNA was synthesized from 2 µg of total RNA using the Super Script II First-Strand Synthesis kit and an oligo (dT) primer system (Invitrogen). An IL-8 TaqMan probe (assay ID: Hs00174103_m1) was purchased from Applied Biosystems (Tokyo, Japan). For quantitative analysis, the TBP gene was used as an internal reference to normalize the input cDNA. PCR was performed using a Gene Amp 7700 Sequence Detection System and its software (Applied Biosystems). The comparative Ct method was used to compute the relative expression values.

Enzyme-linked immunosorbent assay

Twenty-four hours after 1 × 10⁵ cells were plated in each well of a 6-well plate, the culture medium was replaced with 2 ml of growth medium containing MK615 at different concentrations. Forty-eight hours after MK615 treatment, the IL-8 protein concentration in the culture medium of H1792 cells was determined using an enzyme-linked immunosorbent assay (ELISA) with a human IL-8 duo set kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s protocol.

Statistical analysis

Statistical analysis were performed using GraphPad Prism, version 5.0 for Mac OS X (GraphPad Software, San Diego, CA). A P<0.05 was considered statistically significant.

Results

The effect of MK615 on cell growth varies among NSCLC cell lines

We first evaluated the effect of MK615 on the in vitro cell growth of nine NSCLC cell lines and the HBE4C4 immortalized bronchial epithelial cell line, which served as a non-cancerous control (Figure 2A). MK615 significantly inhibited the growth of the H661, H838, H1299, H1395, H1395 and HCC827 cells at ≥5 µl/ml and that of H1792 cells at ≥1 µl/ml, whereas <10 µl/ml MK615 did not affect HBE4C4 cell growth. In contrast, some cell lines exhibited MK615 resistance; 10 µl/ml MK615 significantly but weakly inhibited H441 cell growth, and a significant growth-inhibitory effect was not observed in H460 cells even at a 10 µl/ml.

The proportions of viable cells after 48 h of MK615 treatment are summarized in Figure 2B and Table 1. The proportion of viable cells was significantly lower for H661, H838, H1299 and H1397 cells treated with ≥5 µl/ml MK615, and the value was significantly higher for H441 and H460 cells treated with 10 µl/ml compared to the HBE4C4 non-cancerous control. These results indicate that the majority of NSCLC cell lines are sensitive to MK615 and that the growth-inhibitory effect varies among cell lines.

The MK615 cytotoxic effects involve autophagy induction and G0/G1 cell-cycle arrest in NSCLC cells

A previous study demonstrated that autophagy is induced by MK615 in colon cancer cells [5]. Therefore, to evaluate the mechanisms of MK615-mediated cell death in NSCLC cells, we next examined...
Figure 2: (A) The effect of MK615 on the in vitro cell growth of nine NSCLC cell lines and the HBEC4 immortalized bronchial epithelial cell line, which serves as a non-cancerous control. *, P<0.001; **, P<0.01; †, P<0.05 for comparisons with the non-treatment control (0 µl/ml) by ANOVA using Bonferroni multiple comparisons. The dots represent the mean ± SD from four independent experiments. (B) The cell viabilities (%) of nine NSCLC cell lines and the HBEC4 cell line at 48 h post 5 µl/ml and 10 µl/ml MK615 treatment. *, P<0.001; **, P<0.01; †, P<0.05 for comparisons with the HBEC4 cell viabilities by ANOVA using Bonferroni multiple comparisons. The dots represent the mean ± SD from four independent experiments.
whether autophagy is induced by the MK615 treatment using the 
H1299 and H157 cell lines because these lines are highly sensitive 
to the cytotoxic effect of MK615. To test this idea, we performed 
immunostaining of LC3, which is a yeast Apg8 mammalian homologue, 
for visualizing autophagosome formation because it is associated with 
autophagosomal membranes in its membrane-bound form [15,16]. 
An increase in LC3 expression was clearly observed in the H1299 and 
H157 cell lines after 6 hours of MK615 treatment, as compared to the 
non-treatment control (Figure 3A). The induction of autophagy was 
further confirmed by Western blot analysis showing that the ratios of 
the levels of LC3-II, which represents the autophagosome-associating 
form of LC3, to the levels of LC3-I were increased in MK615-treated 
H1299 cells, as compared to the levels in the untreated cells (Figure 3B). 
These results suggest that autophagy is involved in MK615-mediated 
cell death in NSCLC cells.

We further examined the MK615 effect on the cell cycle in H1299 
and H157 cells. After ≥5 µl/ml MK615 treatment for 24 h, there was an 
increase in the proportion of cells in the G0-G1 phase and a decrease 
in the S phase in both cell lines (Figure 4 & Table 2), suggesting that 
MK615 induces G0-G1 cell-cycle arrest in NSCLC cells.

MK615 inhibits IL-8 mRNA expression and protein 
production in NSCLC cells

In H1792 cells, ≥1 µl/ml MK615 modestly inhibited cell growth 
(Figure 2A); however, the induction of autophagy was not obvious 
in this cell line (data not shown), suggesting that other MK615-
mediated growth inhibition mechanisms may exist. We recently found 
that H1792 cells, which harbor KRAS mutations, highly express IL-8 
through ERK-MAPK pathway activation and that IL-8 attenuation 
resulted in the growth inhibition of this cell line [17]. In addition, a

Citation: Sunaga N, Hiraishi K, Ishizuka T, Kaira K, Iwasaki Y, et al. (2011) MK615, A Compound Extract from the Japanese Apricot "Prunus mume" Inhibits In vitro Cell Growth and Interleukin-8 Expression in Non-small Cell Lung Cancer Cells. J Cancer Sci Ther S11:002. doi:10.4172/1948-5956.S11-002

Table 1: The percentage of viable cells after MK615 treatment in nine NSCLC cell lines and the HBEC4 immortalized bronchial epithelial cell line.

| Cell line | Day 2  | Day 4  | | Day 2  | Day 4  | | Day 2  | Day 4  |
|-----------|--------|--------| |     |     | |     |     |
|           | 5 µl/ml | 10 µl/ml | | 5 µl/ml | 10 µl/ml | | 5 µl/ml | 10 µl/ml |
| HBEC4     | 103.2 ± 10.1 | 44.5 ± 8.5 | | 99.6 ± 15.2 | 29.9 ± 5.3 | |       |     |
| H661      | 38.2 ± 9.2 | 0.0 ± 0.0 | | 23.3 ± 3.8 | 0.0 ± 0.0 | |       |     |
| H838      | 51.8 ± 4.4 | 16.0 ± 1.0 | | 62.1 ± 1.5 | 12.1 ± 3.0 | |       |     |
| H1299     | 56.2 ± 9.2 | 0.0 ± 0.0 | | 40.2 ± 1.8 | 0.0 ± 0.0 | |       |     |
| H157      | 54.5 ± 6.2 | 23.1 ± 6.6 | | 47.9 ± 11.5 | 14.2 ± 5.3 | |       |     |
| H1395     | 77.3 ± 4.9 | 40.8 ± 7.9 | | 74.9 ± 5.1 | 29.6 ± 4.6 | |       |     |
| H1792     | 82.7 ± 4.2 | 48.5 ± 11.6 | | 73.8 ± 4.7 | 36.3 ± 7.1 | |       |     |
| HCC827    | 83.8 ± 4.2 | 63.8 ± 11.6 | | 66.3 ± 11.3 | 48.1 ± 5.6 | |       |     |
| H441      | 93.8 ± 1.7 | 67.8 ± 11.4 | | 77.4 ± 10.9 | 56.9 ± 12.9 | |       |     |
| H460      | 84.8 ± 11.8 | 80.0 ± 10.1 | | 93.0 ± 17.0 | 79.8 ± 19.6 | |       |     |

Table 2: Cell cycle distribution in MK615-treated H157 and H1299 cells.

| Cell line | G0/G1 | S | G2/M | G0/G1 | S | G2/M |
|-----------|-------|---|------|-------|---|------|
| H157      | 50.3  | 16.8 | 32.9 | 48.8  | 20.3 | 30.9 |
| H1299     | 64.5  | 14.0 | 21.5 | 52.6  | 16.2 | 31.2 |
| 5 µl/ml   | 63.4  | 15.5 | 21.1 | 55.6  | 13.8 | 30.6 |

Figure 3: (A) Autophagosome formation by MK615 treatment (10 µl/ml) in the H1299 and H157 cell lines for 6 h. An increase of LC3 expression was clearly observed after 6 h treatment in both cell lines, as compared to the non-treatment control. (B) Western blot analysis of LC3 expression in MK615-treated (10 µl/ml) and untreated H1299 cells for 4 and 8 h. The ratios of the LC3-II/LC3-I levels were increased at 4 and 8 h MK615 post-treatment, as compared to the non-treatment control. ß-Actin expression levels were used as a loading control.
MK615, a compound extract from the Japanese apricot “Prunus mume” inhibits In vitro cell growth and interleukin-8 expression in non-small cell lung cancer cells. J Cancer Sci Ther 2011: S11:002. doi: 10.4172/1948-5956.S11-002

Discussion

This is the first report to demonstrate the inhibitory effects of MK615 on in vitro cell growth and IL-8 expression in NSCLC cells. MK615 contains several triterpenoids including triterpenic acids (e.g., oleanolic acid and ursolic acid) and phytosterols (e.g., β-sitosterol) [9,18,19], which are widely present in natural foods and plants [20]. Given that these triterpenoids have been shown to have anti-inflammatory [21,22] and anti-tumor activities [23-26], some triterpenoids in MK615 appear previous study demonstrated that MK615 inhibits the LPS-induced activation of MAPK pathways in macrophage-like cells [11]. These findings prompted us to investigate whether MK615 treatment results in the down-regulation of IL-8 expression in H1792 cells. IL-8 mRNA expression was significantly reduced by ≥0.5 µl/ml MK615 treatment in a dose-dependent manner (Figure 5). Consistent with this result, we observed the dose-dependent reduction of IL-8 protein levels in H1792 cells (Figure 5). These results suggest that MK615 inhibits cell growth by down-regulating IL-8 expression in some NSCLC cells.

Figure 4: Fluorescence-activated cell sorting profiles of MK615-treated (i.e., 5 µl/ml and 10 µl/ml) and untreated (control) H1299 and H157 cells. The horizontal and vertical axes represent the DNA content and cell number, respectively.

Figure 5: MK615 mediates the down-regulation of IL-8 expression at the mRNA and protein levels in IL-8 overexpressing H1792 cells. The columns represent the mean ± SD from three independent experiments. *, P<0.0001; **, P<0.001; ***, P<0.01 for comparisons of the non-treatment control (0 µl/ml) by ANOVA using Bonferroni multiple comparison.
to be the key substances relevant to the anti-tumor and anti-IL-8 effects in NSCLC cells.

While MK615 inhibited the in vitro cell growth of the majority of the NSCLC cell lines tested, the growth-inhibitory effects varied among the cell lines, and some cell lines exhibited MK615 resistance. Previous studies indicate that MK615 inhibits cell growth through the inhibition of the Aurora A and B kinases [8,10]. They indicate that the growth-inhibitory effect may depend on the expression level of the Aurora A and B kinases. More recently, Sakuraoaka et al. [7] reported that MK615 down-regulates the expression of advanced glycation end-product (AGE)-receptor (RAGE), which in turn inhibits AGE-stimulated cell growth in hepatocellular carcinoma cells, where RAGE is highly expressed [7]. These findings suggest that the MK615 growth-inhibitory effects may depend on the endogenous expression levels of the Aurora A and B kinases and RAGE. Further studies are needed to verify whether the Aurora A and B kinases and RAGE contribute to MK615 sensitivity and to investigate whether there are other molecular mechanisms responsible for MK615 sensitivity in cancer cells.

In this study, we observed autophagosome formation in NSCLC cells early after MK615 treatment. Autophagy is a process of self-cannibalization, which is classified as type II programmed cell death [27]. Collecting evidence highlight the essential role of autophagy in the regulation of cancer cell survival [28]. Autophagic cell death is morphologically characterized by the formation of cytoplasmic vacuoles, and this morphological change was observed in MK615-treated breast cancer cells [6]. In addition, Mori et al. [5] reported that MK615 induces autophagy in colon cancer cells. These observations suggest that the induction of autophagy is one of the mechanisms of MK615-mediated cancer cell death. Of note, previous studies have demonstrated that several triterpenoids including ursolic acid induce autophagy in cancer cells [25,29-31]. Although the precise mechanisms of MK615-mediated autophagy induction remain unknown, some of the triterpenoids in MK615 may play important roles in the autophagic cell death of cancer cells.

We found that MK615-treated cells accumulated in the G0-G1 phase, and this was accompanied by a decrease of cells in the S phase in H1299 and H157 NSCLC cells, suggesting that MK615 has the ability to induce G0-G1 arrest in NSCLC cells. MK615 contains oleanolic acid and ursolic acid, and both possibly induce G0-G1 cell cycle arrest. It has been shown that G0-G1 arrest is induced by oleanolic acid in osteosarcoma cells [32] and by ursolic acid in prostate cancer [25] and hepatocellular carcinoma cells [33]. In contrast, previous studies reported that MK615 induces G2-M arrest in breast [6], pancreatic [10] and esophageal cancers [10]. These inconsistent results may be due to the difference in the type of cancer cells.

Inflammation has been thought to play essential roles in tumor development and progression [34]. One of the most important cancer-related inflammatory chemokines is the CXC chemokine interleukin-8 (IL-8), which serves as an angiogenic growth factor in several types of cancers including NSCLC [35]. We recently reported that KRAS-mutant NSCLC cell lines, including H1792, overexpress IL-8 through ERK-MAPK pathway activation [17]. In this study, the treatment of H1792 cells with MK615 resulted in a significant reduction in the IL-8 mRNA expression and protein production in a dose-dependent manner. Given that MK615 was shown to inhibit LPS-induced ERK phosphorylation [11], it is likely that MK615 inactivates the ERK-MAPK pathway, leading to the transcriptional down-regulation of IL-8 expression in NSCLC cells. Because IL-8 is a potent angiogenic factor, it is also likely that MK615 has the potential to suppress tumor angiogenesis in NSCLC cells.

In conclusion, we demonstrated that MK615 has multiple anti-tumor activities in NSCLC cells. Together with previous studies demonstrating the MK615 anti-tumor activities in various cancer types [4-10], our results strengthen the evidence indicating that MK615 is an anti-tumor agent. Further in vivo studies will be necessary to evaluate the therapeutic efficacy of MK615 in NSCLC.

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research (C) (grant #23591134) from the Japan Society for the Promotion of Science. We thank Drs. Takeshi Hsada and Yosuke Kamide of the Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan for technical support and critical advice.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Larsen JE, Minna JD (2011) Molecular biology of lung cancer: clinical implications. Clin Chest Med 32: 703-740.
3. Adachi M, Suzuki Y, Mizuta T, Osawa T, Adachi T, et al. (2007) The “Prunus mume Sieb. et Zucc” (Ume) is a Rich Natural Source of Novel Anti-Cancer Substance. Int J Food Prop 10: 375-384.
4. Tada Ki, Kahwara Ki, Matsushita S, Hashiguchi T, Maruyama I, et al. (2011) MK615, a Prunus mume Sieb. Ell Zucc (‘Ume’) Extract, Attenuates the Growth of A375 Melanoma Cells by Inhibiting the ERK1/2-Id-1 Pathway. Phytother Res.
5. Mori S, Sawada T, Okada T, Osawa T, Adachi M, et al. (2007) New anti-proliferative agent, MK615, from Japanese apricot “Prunus mume” induces striking autophagy in colon cancer cells in vitro. World J Gastroenterol 13: 6512-6517.
6. Nakagawa A, Sawada T, Okada T, Ohsawa T, Adachi M, et al. (2007) New antineoplastic agent, MK615, from UME (a Variety of) Japanese apricot inhibits growth of breast cancer cells in vitro. Breast J 13: 44-49.
7. Sakuraoaka Y, Sawada T, Okada T, Shiraiki T, Miura Y, et al. (2010) MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 16: 5334-5341.
8. Okada T, Sawada T, Osawa T, Adachi M, Kubota K (2007) A novel anti-cancer substance, MK615, from ume, a variety of Japanese apricot, inhibits growth of hepatocellular carcinoma cells by suppressing Aurora A kinase activity. Hepatogastroenterology 54: 1770-1774.
9. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, et al. (2009) Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 125: 952-960.
10. Okada T, Sawada T, Osawa T, Adachi M, Kubota K (2008) MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. World J Gastroenterol 14: 1378-1382.
11. Morimoto Y, Kikuchi K, Ito T, Tokuda M, Matsuyama T, et al. (2009) MK615 attenuates Porphyromonas gingivalis lipopolysaccharide-induced pro-inflammatory cytokine release via MAPK inactivation in murine macrophage-like RAW264.7 cells. Biochem Biophys Res Commun 389: 90-94.
12. Phillips RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCIL-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91.
13. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, et al. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235.
14. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization
of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.

15. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.

16. Suzuki T, Nakagawa M, Yoshikawa A, Sasagawa N, Yoshimori T, et al. (2002) The first molecular evidence that autophagy relates rimmed vacuole formation in chloroquine myopathy. J Biochem 131: 647-651.

17. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, et al. (2012) MK615, a prospective anti-proliferative agent, enhances CD4/CD8 ratio after exposure to irradiation. Int J Radiat Biol 87: 81-90.

18. Al-Jahdari WS, Sakurai H, Yoshida Y, Mobaraki A, Suzuki Y, et al. (2011) MK615, A Compound Extract from the Japanese Apricot “Prunus mume” Inhibits In vitro Cell Growth and Interleukin-8 Expression in Non-small Cell Lung Cancer Cells. J Cancer Sci Ther S11:002. doi:10.4172/1948-5956.S11-002

19. Kawahara K, Hashiguchi T, Masuda K, Sanibadi AR, Kikuchi K, et al. (2009) Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. Int J Mol Med 23: 615-620.

20. Liu J (2005) Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 100: 92-94.

21. Singh GB, Singh S, Bani S, Gupta BD, Banerjee SK (1992) Anti-inflammatory activity of oleanolic acid in rats and mice. J Pharm Pharmacol 44: 456-458.

22. Giner-Larza EM, Márquez S, Recio MC, Giner RM, Prieto JM (2001) Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity. Eur J Pharmacol 428: 137-143.

23. Hsu YL, Kuo PL, Lin CC (2004) Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 75: 2303-2316.

24. Lúcio KA, Rocha Gda G, Mongão-Ribeiro LC, Fernandes J, Takiya CM (2011) Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PloS One 6: e28596.

25. Shin SW, Kim SY, Park JW (2012) Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. Biochim Biophys Acta 1823: 451-457.

26. Choi YH, Kong KR, Kim YA, Jung KO, Kil JH, et al. (2003) Induction of Bax and activation of caspases during beta-sitosterol-mediated apoptosis in human colon cancer cells. Int J Oncol 23: 1657-1662.

27. Bursch W, Ellinger A, Gerner C, Fröhwein U, Schulte-Hermann R (2000) Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Annu N Y Acad Sci 926: 1-12.

28. Kondo Y, Kanazawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 729-734.

29. Ellington AA, Berhow MA, Singletary KW (2006) Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasapogenins in colon cancer cells. Carcinogenesis 27: 298-306.

30. Xu ZX, Liang J, Haridas V, Gaikwad A, Connolly FP, et al. (2007) A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell Death Differ 14: 1948-1957.

31. Li DD, Guo JF, Huang JJ, Wang LL, Deng R, et al. (2010) Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PloS One 5: e12176.

32. Zhou R, Zhang Z, Zhao L, Jia C, Xu S, et al. (2011) Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells. J Orthop Res 29: 846-852.

33. Tian Z, Lin G, Zheng RX, Huang F, Yang MS, et al. (2006) Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana. World J Gastroenterol 12: 874-879.

34. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.

35. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.